Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Volpara (ASX:VHT) share price on watch after Natera partnership

The Volpara Health Technologies Ltd (ASX:VHT) share price is on watch as it announced a collaboration with leading genetics company Natera.

The Volpara Health Technologies Ltd (ASX: VHT) share price is on watch as it announced a collaboration with leading genetics company Natera.

Volpara partners with Natera

Breast screening software business Volpara has entered into a partnership with Natera Inc (NASDAQ: NTRA). Volpara called Natera a global leader in cell-free DNA testing with a market cap of more than US$10 billion, to bring Natera’s ‘Empower Hereditary Cancer Test’ to Volpara’s customers in the US.

Customers use Volpara’s market-leading breast cancer risk assessment software to make decisions for triaging patients to supplemental imaging and/or genetic testing based on their personalised risk.

Risk assessment is also required by many US insurance companies before additional testing. Genetic testing assists in earlier cancer detection and is critical in reducing treatment costs and increasing the chance of surviving.

Volpara plans to create a fully integrated ordering process for Natera genetic testing services within the Volpara breast health platform.

As part of the agreement, Volpara said it has the potential to offer increased value to mutual customers after successful clinical implementation.

Management comments

Volpara CEO Dr Ralph Highnam said:

By adding Natera to our breast health platform, we continue to build our integrations with best-of-breed genetic testing companies in order to offer our customers greater options. Natera will allow us to continue driving the adoption of personalised breast cancer screening in the US. We continue to see strong interest in our risk offerings and the ability to direct women to the appropriate genetic testing at the right time.”

Summary thoughts about the partnership and the Volpara share price

The stronger the offering that Volpara can offer clients, the better off it will be. Hopefully this partnership will enable the ASX healthcare share to increase its average revenue per user even further over time. It is building a formidable array of services that it can offer to people.

It’s one of the ASX growth shares that I am paying close attention to.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content